Cleerly

High-Level Overview

Cleerly is a digital healthcare company developing an AI-driven platform that analyzes coronary computed tomography angiography (CCTA) images to quantify and assess coronary artery disease (CAD), delivering clinically actionable insights for personalized heart disease treatment and prevention.[1][2][3] It serves clinicians, cardiologists, and healthcare providers by solving the problem of imprecise CAD diagnosis through precise plaque volume, composition, stenosis severity, and ischemia evaluation, potentially reducing unnecessary tests and enabling earlier intervention.[1][3] Cleerly's growth momentum includes FDA-cleared technology, major clinical trials like CREDENCE and PACIFIC demonstrating superior accuracy over alternatives, recent $106 million funding led by Insight Partners, expanding payer coverage to 61 million Americans, and late-breaking presentations at conferences like RSNA 2024, TCT 2025, and CVCT 2025.[1][4][5]

Origin Story

Cleerly emerged as a mission-driven company focused on transforming heart disease care by shifting from symptom-based to proactive, AI-powered analysis of atherosclerosis.[1][2] While specific founders are not detailed in available sources, the company has rapidly advanced from developing its core CCTA analysis platform to achieving FDA clearance and clinical validation through multicenter trials like CREDENCE, which showed Cleerly ISCHEMIA outperforming FFRCT and stress testing against invasive FFR gold standards.[1] Pivotal early traction came from post-hoc PACIFIC study analyses confirming its prognostic value for major adverse cardiac events (MACE), alongside securing $106 million in funding to scale its solutions.[1][4][5]

Core Differentiators

• AI-Powered Precision Imaging: Generates 3D reconstructions of coronary arteries, quantifying plaque types (e.g., non-calcified), volume, length, location, and stenosis in 2D/3D, surpassing traditional methods in accuracy.[1][3]
• Ischemia Detection and Prognostication: Cleerly ISCHEMIA workflow predicts ischemia without invasives, proven superior in CREDENCE (higher AUC vs. FFRCT/stress testing) and prognostic for MACE in PACIFIC, unlike competitors.[1]
• Clinical and Prognostic Insights: Tracks disease progression over time, supports personalized plans (lifestyle, meds), and identifies high-risk non-obstructive CAD with 12-fold risk gradients per CONFIRM2 registry.[3][4][5]
• Accessibility and Integration: Web-based, FDA-cleared, with payer adoption (e.g., UnitedHealthcare), patient education tools, and seamless workflow for practices like Capital Cardiology.[1][3][4]

Role in the Broader Tech Landscape

Cleerly rides the wave of AI in precision medicine and cardiac imaging, addressing CAD—the leading global cause of death—by enabling earlier, non-invasive detection amid rising demand for personalized care.[1][2] Timing aligns with advancing CCTA adoption, post-pandemic focus on preventive cardiology, and AI regulatory progress (FDA clearance), amplified by payer expansions improving access.[4] Market forces like aging populations, trial-validated AI superiority, and registries like CONFIRM2 position it to influence standards, reducing heart attacks via plaque-focused risk stratification over stenosis alone.[1][4][5]

Quick Take & Future Outlook

Cleerly is poised to redefine CAD management as payer coverage grows and trials like CONFIRM2 solidify its prognostic edge, potentially becoming the new care standard.[4][5] Trends in AI-quantitative imaging, high-burden plaque thresholds, and multimodal data integration will shape its path, evolving influence through broader clinician adoption and outcomes data. This builds on its core mission: act early with AI to eliminate preventable heart attacks.[1]